PPARδ agonists are hypothesized to reduce risk for AD because they regulate glucose and fatty acid utilization and enhance anti-oxidant and anti-inflammatory signaling (Liu Y. et al., 2018). The gene discussed is PPARD; the disease is Alzheimer disease.